These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24286231)

  • 1. Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy.
    Álvarez JC; Cuervo SI; Garzón JR; Gómez JC; Díaz JA; Silva E; Sánchez R; Cortés JA
    BMC Pharmacol Toxicol; 2013 Nov; 14():59. PubMed ID: 24286231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
    Varghese JM; Jarrett P; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.
    Bauer SR; Salem C; Connor MJ; Groszek J; Taylor ME; Wei P; Tolwani AJ; Fissell WH
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):452-7. PubMed ID: 22282479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders.
    Sano H; Kobayashi R; Suzuki D; Hori D; Kishimoto K; Kobayashi K
    Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27873451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
    Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
    Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia.
    Bucaneve G; Micozzi A; Picardi M; Ballanti S; Cascavilla N; Salutari P; Specchia G; Fanci R; Luppi M; Cudillo L; Cantaffa R; Milone G; Bocchia M; Martinelli G; Offidani M; Chierichini A; Fabbiano F; Quarta G; Primon V; Martino B; Manna A; Zuffa E; Ferrari A; Gentile G; Foà R; Del Favero A
    J Clin Oncol; 2014 May; 32(14):1463-71. PubMed ID: 24733807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.
    Shotwell MS; Nesbitt R; Madonia PN; Gould ER; Connor MJ; Salem C; Aduroja OA; Amde M; Groszek JJ; Wei P; Taylor ME; Tolwani AJ; Fissell WH
    Clin J Am Soc Nephrol; 2016 Aug; 11(8):1377-1383. PubMed ID: 27197907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial.
    Sime FB; Roberts MS; Tiong IS; Gardner JH; Lehman S; Peake SL; Hahn U; Warner MS; Roberts JA
    J Antimicrob Chemother; 2015 Aug; 70(8):2369-75. PubMed ID: 25953805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose optimization of piperacillin/tazobactam in critically ill children.
    De Cock PAJG; van Dijkman SC; de Jaeger A; Willems J; Carlier M; Verstraete AG; Delanghe JR; Robays H; Vande Walle J; Della Pasqua OE; De Paepe P
    J Antimicrob Chemother; 2017 Jul; 72(7):2002-2011. PubMed ID: 28387840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
    Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B
    Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tazobactam/piperacillin as an empirical treatment for the patients of adult and child with febrile neutropenia in Japan.
    Tamura K; Akiyama N; Kanda Y; Saito M
    J Infect Chemother; 2015 Sep; 21(9):654-62. PubMed ID: 26141812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
    Sime FB; Hahn U; Warner MS; Tiong IS; Roberts MS; Lipman J; Peake SL; Roberts JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.
    Sanz MA; López J; Lahuerta JJ; Rovira M; Batlle M; Pérez C; Vázquez L; Julià A; Palau J; Gutiérrez M; Capote FJ; Ramos F; Benlloch L; Larrea L; Jarque I;
    J Antimicrob Chemother; 2002 Jul; 50(1):79-88. PubMed ID: 12096010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.
    Marie JP; Marjanovic Z; Vekhoff A; Bouvet A; Chast F; Levy V; Baudard M; Legrand O; Rio B; Delmer A; Zittoun R
    Support Care Cancer; 1999 Mar; 7(2):89-94. PubMed ID: 10089089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.
    Felton TW; Hope WW; Lomaestro BM; Butterfield JM; Kwa AL; Drusano GL; Lodise TP
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4087-94. PubMed ID: 22585219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical effects and safety of piperacillin/tazobactam in treating neutropenic febrile patients with malignant hematopathy].
    Lu KY; Jia JS; Li J; Wang C; Wu DP; Hu LD; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2009 Jan; 89(1):41-4. PubMed ID: 19489243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Shea KM; Kays MB
    J Clin Pharmacol; 2015 Aug; 55(8):899-908. PubMed ID: 25823963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants.
    Li Z; Chen Y; Li Q; Cao D; Shi W; Cao Y; Wu D; Zhu Y; Wang Y; Chen C
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1223-33. PubMed ID: 23354809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.
    Shea KM; Cheatham SC; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2009 Nov; 34(5):429-33. PubMed ID: 19726163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
    Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
    Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.